Comparative Pharmacology
Head-to-head clinical analysis: NUCYNTA ER versus VICODIN HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUCYNTA ER versus VICODIN HP.
NUCYNTA ER vs VICODIN HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor, providing analgesic effects through opioid receptor activation and modulation of descending pain pathways.
Hydrocodone is a mu-opioid receptor agonist that inhibits ascending pain pathways; acetaminophen inhibits cyclooxygenase and has antipyretic effects.
100 mg orally every 12 hours, titrated from 50 mg every 12 hours; maximum 200 mg every 12 hours.
One tablet (hydrocodone bitartrate 10 mg/acetaminophen 660 mg) orally every 4-6 hours as needed for pain; maximum 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life: 4.1 hours (range 3.3–4.7 h) after single oral dose; steady state: 4.4 h. No clinically relevant accumulation.
Hydrocodone: 3.8-5.5 hours (mean 4.5 h). Acetaminophen: 2-3 hours. Clinical context: dosing interval every 4-6 hours for acute pain.
Renal: 99% (tapentadol and glucuronide conjugates); Fecal: <1%; unchanged tapentadol: <5%.
Primarily renal: hydrocodone is eliminated as conjugated metabolites (glucuronides) ~80%; unchanged drug ~5%. Biliary/fecal: minor, <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic